Holen Sie sich die Stockscreener-App
342.76
1.81%
-8.50
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - Kalkine Media
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan
Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan
Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - AD HOC NEWS
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Krystal Biotech Stock Soars 16% in Three Months: Here's Why - Eastern Progress
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Eastern Progress
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal Biotech Inc (MIL:1KRYS) Stock Price, Trades & News - GuruFocus
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring The 15.87% Upside Potential - DirectorsTalk Interviews
Krystal Biotech Insider Sold Shares Worth $8,227,953, According to a Recent SEC Filing - marketscreener.com
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS - MarketBeat
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile? - simplywall.st
Krystal Biotech (KRYS) Has a New Rating from RBC Capital - The Globe and Mail
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares - GuruFocus
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) Advances 1.2% to $332.27, Holding Ground Above Key SupportAggressive Growth Picks - vinanet.vn
Krystal Biotech (NASDAQ:KRYS) director Dino Rossi sells $8.2m shares - Investing.com Australia
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - The Globe and Mail
RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400 - moomoo.com
KRYS Looks 0.5% Undervalued on GF Value™ - GuruFocus
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says - marketscreener.com
KRYS Initiates Coverage by RBC Capital -- Rating Set to Outperfo - GuruFocus
Krystal Bio wins bullish view at RBC Capital Markets (KRYS) - Seeking Alpha
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More - Yahoo Finance
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target - marketscreener.com
KRYSTAL BIOTECH, INC. : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $400 - Bitget
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus - Sahm
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating - Moomoo
Trading Systems Reacting to (KRYS) Volatility - news.stocktradersdaily.com
Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript - The Globe and Mail
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a 17% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run - Yahoo Finance
Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Krystal Biotech (NASDAQ:KRYS) Upgraded at Chardan Capital - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo Finance
California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS - marketbeat.com
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):